Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Developer of advanced biopharmaceutics intended to treat acute and critical diseases. The company's advanced biopharmaceutics develops new medicines in the areas of hematology, antithrombosis and oncology, enabling people to avail the new generation of drugs.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Other Industries
Drug Discovery
Primary Office
  • C/o Dornbach GmbH
  • Arnulfstra├če 39
  • 80636 Munich
  • Germany

+49 089 00000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Curacyte’s full profile, request a free trial.

Curacyte Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-Jan-2018 000.00 Completed Out of Business
5. Later Stage VC 29-Dec-2012 00.00 000.00 Completed Generating Revenue
4. Grant 000.00 Completed Generating Revenue
3. Secondary Transaction - Private 30-Jun-2012 000.00 Completed Generating Revenue
2. Later Stage VC (Series C) 20-Dec-2005 $37.3M $76.2M Completed Generating Revenue
1. Early Stage VC 01-Jan-2000 $38.9M $38.9M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Curacyte Executive Team (4)

Name Title Board
Helmut Giersiefen Chief Executive Officer

3 Former Executives

You’re viewing 1 of 4 executives. Get the full list »